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MaBACKGROUND Human-induced pluripotent stem cells (iPSCs) are a potentially unlimited source for generation of
cardiomyocytes (iPSC-CMs). However, current protocols for iPSC-CM derivation face several challenges, including
variability in somatic cell sources and inconsistencies in cardiac differentiation efﬁciency.
OBJECTIVES This study aimed to assess the effect of epigenetic memory on differentiation and function of
iPSC-CMs generated from somatic cell sources of cardiac versus noncardiac origins.
METHODS Cardiac progenitor cells (CPCs) and skin ﬁbroblasts from the same donors were reprogrammed into
iPSCs and differentiated into iPSC-CMs via embryoid body and monolayer-based differentiation protocols.
RESULTS Differentiation efﬁciency was found to be higher in CPC-derived iPSC-CMs (CPC-iPSC-CMs) than in ﬁbroblast-
derived iPSC-CMs (Fib-iPSC-CMs). Gene expression analysis during cardiac differentiation demonstrated up-regulation
of cardiac transcription factors in CPC-iPSC-CMs, including NKX2-5, MESP1, ISL1, HAND2, MYOCD, MEF2C, and GATA4.
Epigenetic assessment revealed higher methylation in the promoter region of NKX2-5 in Fib-iPSC-CMs compared with
CPC-iPSC-CMs. Epigenetic differences were found to dissipate with increased cell passaging, and a battery of in vitro
assays revealed no signiﬁcant differences in their morphological and electrophysiological properties at early passage.
Finally, cell delivery into a small animal myocardial infarction model indicated that CPC-iPSC-CMs and Fib-iPSC-CMs
possess comparable therapeutic capabilities in improving functional recovery in vivo.
CONCLUSIONS This is the ﬁrst study to compare differentiation of iPSC-CMs from human CPCs versus human
ﬁbroblasts from the same donors. The authors demonstrate that although epigenetic memory improves differentiation
efﬁciency of cardiac versus noncardiac somatic cell sources in vitro, it does not contribute to improved functional
outcome in vivo. (J Am Coll Cardiol 2014;64:436–48) © 2014 by the American College of Cardiology Foundation.C oronary heart disease is the leading cause ofdeath in developed countries, accounting forapproximately 550,000 deaths annually in the
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ABB R E V I A T I O N S
AND ACRONYMS
CM = cardiomyocyte
CPC = cardiac progenitor cell
cTnT = cardiac troponin T
EB = embryoid body
EC = endothelial cell
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437therapies have emerged as a promising alternative (2).
Human-induced pluripotent stem cells (iPSCs), in partic-
ular, are an attractive donor cell source in view of their ca-
pacity for unlimited self-renewal and pluripotency (3). In
addition, because iPSCs can be derived from various so-
matic tissue sources (4), their use largely circumvents
ethical and immunologic concerns associatedwith embry-
onic stem cell (ESC)–based therapies.SEE PAGE 449
FACS = ﬂuorescence-activated
cell sorting
Fib = ﬁbroblast
iPSC = induced pluripotent
stem cell
MEA = multielectrode array
MI = myocardial infarction
Sca = stem cell antigen
= smooth muscle cellHowever, several studies have demonstrated that
iPSCs are not as similar to ESCs as initially believed (5).
Newer published data suggests that epigenetic memory
has the potential to inﬂuence the differentiationpotential
and functional maturity of iPSC-derived cell types (6).
In this study, the authors aimed to assess the contri-
butions of epigenetic memory to the differentiation po-
tential, function, and maturity of human iPSCs derived
from cardiac and noncardiac sources. To do so, the study
generated human iPSCs from cardiac progenitor cells
(CPC-iPSCs) and dermal ﬁbroblasts (Fib-iPSCs) from the
same donors and differentiated these cells to iPSC-CMs
for in vitro and in vivo characterization. Because hu-
man CPCs have been shown to give rise to multiple lin-
eages of cells found in the heart (7–9), the authors also
compared the ability of CPC-iPSCs and Fib-iPSCs to
differentiate into other cell types found in the heart.
METHODS
A detailed Methods section is available in the Online
Appendix. Stanford University (Stanford, California)
Human Subjects Research Institutional Review Board
approved all the protocols in this study. iPSCs were
generated using lentiviral transduction, as previously
described (4). A modiﬁed protocol from Yang et al.
(10) was followed to differentiate iPSC-CMs by
3-dimensional (3D) embryoid body (EB) formation. As
an alternate method of cardiac differentiation, a
2-dimensional (2D) monolayer protocol from Lian
et al. (11) was also used. Following differentiation,
iPSC-CMs were cultured in vitro using SCT Cardiac
Maintenance Media (Stem Cell Theranostics, Menlo
Park, California). A detailed description is included in
the Methods section in the Online Appendix.
STATISTICAL ANALYSIS. Normality distribution was
studied with the Kolmogorov-Smirnov test (p < 0.05).
Statistically signiﬁcant differences were determined
using the Mann-Whitney test or Wilcoxon signed rank
test, with alpha set to 0.05 for samples not displaying a
normal distribution, and with Student t test or paired
Student t test, with alpha set to 0.05 for samples with
a normal distribution. Unless speciﬁed, data areexpressed as mean  SEM. All statistical anal-
ysis was carried out using Prism5 (GraphPad
Software, La Jolla, California).
RESULTS
Skin ﬁbroblasts and CPCs were isolated from
2 matched human fetal donors (Fig. 1A). To
perform CPC isolation, heart tissue was
digested to a single cell suspension and
labeled with Sca-1 antibody for magnetic cell
sorting (12). Following a brief period of cell
expansion, fetal CPCs and ﬁbroblasts were
characterized for gene expression. Fetal CPCs
were found to express genes associated with
cardiac lineage, such as KDR, NKX2-5, TBX18,
WT1 MEF2C, and GATA4, whereas ﬁbroblasts
expressed only TBX18 (Online Fig. 1A). Neither the
CPCs nor ﬁbroblasts were found to express genes
associated with pluripotency such as NANOG and
OCT4, both of which were highly expressed in iPSCs
(Online Fig. 1B). CPCs and ﬁbroblasts were subse-
quently reprogrammed through lentiviral infection
using OCT4, SOX2, KLF4, and c-MYC (3). After
approximately 3 weeks, colonies positive for alkaline
phosphatase (Fig. 1B) with ESC-like morphology were
mechanically isolated and expanded on Matrigel-
coated dishes. No differences in reprogramming ef-
ﬁciency were observed between the 2 cell types. Both
CPC-iPSCs and Fib-iPSCs exhibited identical mor-
phologies and presence of pluripotency markers such
as Tra-1-60, and Oct4 (Fig. 1B). Teratoma formation
assays using CPC-iPSCs and Fib-iPSCs produced de-
rivatives from all 3 germ layers (Fig. 1C). Paired CPC-
iPSCs and Fib-iPSCs also were generated from an
adult 65-year old donor as an additional control.
Reprogramming was conducted in a manner identical
to that used in fetal donor sources. Adult CPC-iPSCs
and Fib-iPSCs similarly exhibited ESC-like morphol-
ogies and markers of pluripotency (Online Fig. 2).
Following iPSC characterization and a brief period
of cell expansion, CPC-iPSCs and Fib-iPSCs were
differentiated into iPSC-CMs via 3D EB formation
(Online Fig. 3A) (10). At day 15 following induction of
cardiac differentiation, spontaneously beating EBs
were observed under brightﬁeld microscopy. Beating
EBs were dissociated into single cells and charac-
terized by confocal microscopy for immunostaining
against cardiac-speciﬁc markers, such as cardiac
troponin T (cTnT) and sarcomeric alpha-actinin
(Fig. 2A, Online Fig. 3B). A ﬂuorescence-activated
cell sorting (FACS) analysis of dissociated EBs
conﬁrmed a signiﬁcantly higher percent of cTnT-
positive cells in CPC-iPSC-CMs than in Fib-iPSC-CMs
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FIGURE 1 iPSC Generation and Characterization
(A) Skin ﬁbroblast and cardiac progenitor cell (CPC) primary cultures were established from the same donors and reprogrammed with the
pluripotency transcription factors Oct4, Sox2, Klf4, and c-Myc. (B) Successfully reprogrammed induced pluripotent stem cells (iPSCs) express
standard markers of pluripotency such as alkaline phosphatase (AP), Tra-1-60 (red), and Oct4 (green). (C) Following transplantation into
immunodeﬁcient mice, CPC-iPSCs and Fib-iPSCs give rise to 3-germ layer teratomas containing endoderm (epithelium), mesoderm (cartilage),
and ectoderm (neural rosettes and pigments).
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438from the same donor (46.2  5.9% vs. 34.0  6.4%,
n ¼ 12; p < 0.05) (Fig. 2B). Quantiﬁcation of beating
EBs at early passage (between 15 and 30) also
revealed a higher number of beating EBs for CPC-
iPSC-CMs as compared with Fib-iPSC-CMs (40.0 
8.9% vs. 19.8  5.2%, n ¼ 10; p < 0.05) (Fig. 2C), thus
indicating higher cardiac differentiation efﬁciencies
for CPC-iPSC-CMs.
To conﬁrm ﬁndings that elevated cardiac differ-
entiation efﬁciency in CPC-iPSC-CMs was not spe-
ciﬁc to EB-based methods of cardiac differentiation,
the authors also utilized a 2D monolayer differenti-
ation protocol on the basis of Lian et al. (Online
Fig. 4A) (11). Fetal CPC-iPSC-CMs and Fib-iPSC-CMsgenerated through monolayer differentiation exhibi-
ted the same cardiac markers as iPSC-CMs generated
through 3D EB differentiation (Online Fig. 4B). FACS
analysis of dissociated monolayers demonstrated a
signiﬁcantly higher percent of cTnT-positive cells
in fetal CPC-iPSC-CMs compared with Fib-iPSC-CMs
from the same donor (57.2  0.9% vs. 51.7  0.9%,
n ¼ 14; p < 0.05) (Online Figs. 5A and 5B). Immuno-
staining quantiﬁcation for cTnT-positive cells using
2D monolayer protocol also revealed signiﬁcantly
higher cardiac differentiation efﬁciencies for CPC-
iPSC-CMs compared with Fib-iPSC-CMs (64.7  1.3%
vs. 54.5  1.4%, n ¼ 20; p < 0.05) (Online Figs. 6A
and 6B). Analysis of paired CPC-iPSC-CMs and
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FIGURE 2 Characterization of Induced Pluripotent Stem Cell–Derived Cardiomyocytes
(A) Immunostaining of cardiac progenitor cell-derived induced pluripotent stem cell-derived cardiomyocytes (CPC-iPSC-CMs) and ﬁbroblast-
derived induced pluripotent stem cell-derived cardiomyocytes (Fib-iPSC-CMs) for cardiac-speciﬁc markers. Pictures show cardiac troponin T
(red), sarcomeric alpha-actinin (green), and DAPI (blue). (B) Quantiﬁcation of the percentage of cells positive for cardiac troponin T (cTnT) as
determined by ﬂuorescence-activated cell sorting (n ¼ 12) at day 15 after cardiac differentiation. The percentage of cTnT positive cells is
signiﬁcantly (*p < 0.05) higher in CPC-iPSC-CMs compared with Fib-iPSC-CMs. (C) Quantiﬁcation of the percentage of beating embryoid bodies
(EBs) at day 15 post-cardiac differentiation of CPC-iPSCs and Fib-iPSCs (n ¼ 10). The percentage of CPC-iPSC beating EBs is signiﬁcantly higher
(*p < 0.05) than Fib-iPSC beating EBs.
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439Fib-iPSC-CMs derived from a 65-year-old adult donor
further conﬁrmed results observed in fetal lines.
FACS of adult lines demonstrated increased cardiac
differentiation for CPC-iPSC-CMs versus Fib-iPSC-CMs
(43.1  3.7% vs. 35.2  3.5%, n ¼ 7; p < 0.05) (Online
Figs. 7A and 7B). Immunomicroscopy quantiﬁcation
for cTnT-positive cells also yielded similar results in
CPC-iPSC-CMs versus Fib-iPSC-CMs (64.2  2.7% vs.
45.0  1.5%, n ¼ 10; p < 0.05) (Online Fig. 8A and 8B).
However, prolonged culture of iPSCs for >40 passages
negated any differences between CPC-iPSC and Fib-
iPSC lines (Online Figs. 9A and 9B). Taken together,
these results suggest that at low passages (up to pas-
sage 30), derivation of iPSCs from cardiac sources such
as CPCs helps enhance the ability of iPSCs to differen-
tiate into cardiac lineages, but this effect is lost with
further passage.
During generation of cardiomyocytes from iPSCs,
pluripotent cells go through several distinct stages
of differentiation, including the creation of an early
mesoderm, followed by a cardiac mesoderm speciﬁc
to different established cardiovascular lineages (10).To improve their understanding of cardiac differen-
tiation in CPC-iPSC-CMs and Fib-iPSC-CMs, the au-
thors grouped speciﬁc markers into 1) early cardiac
mesodermal transcription factors, 2) cardiovascular
progenitor transcription factors, and 3) late-stage
cardiogenic transcription factors (Online Fig. 10A).
The authors then charted the expression of these
markers over the cardiac differentiation process.
Speciﬁcally, the authors chose MESP1 as a marker for
early cardiac mesoderm, NKX2-5 and ISL1 as markers
for cardiovascular progenitors, and HAND2, MYOCD,
TBX5, GATA4, and MEF2C as markers for more
established cardiac lineages. MESP1 is a transcription
factor necessary for the speciﬁcation of multipotent
cardiovascular progenitors and the expression of
cardiovascular transcription factors (13). HAND2 is a
transcription factor involved in heart development
(14), whereas MYOCD is a transcriptional co-activator
of serum response factor (SRF), which interacts with
TBX5 to promote cardiac gene expression (15). GATA4
is a co-activator of NKX2-5 (16), a transcription factor
involved in heart formation and development (17).
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FIGURE 3 Gene Expression Levels During Cardiac Differentiation
Graphs represent expression levels of (A) early mesodermal transcription factor, (B) early cardiovascular transcription factors, and (C) late-
stage cardiogenic transcription factors during the process of cardiac differentiation. Gene expression levels are normalized to expression levels
in ﬁbroblast-derived induced pluripotent stem cells (Fib-iPSCs) (day 0) to demonstrate expression change over time (n ¼ 2 for day 0 and n ¼ 5
for day 4 and day 8). MESP1, NKX2-5, ISL1, HAND2, MYOCD, and GATA4 levels at day 4 of the cardiac differentiation were signiﬁcantly higher
(p < 0.05) in cardiac progenitor cell-derived induced pluripotent stem cells (CPC-iPSCs) than in Fib-iPSCs. At day 8 of the cardiac differen-
tiation, HAND2 levels were signiﬁcantly higher (p < 0.05) in Fib-iPSCs than in CPC-iPSCs, whereas MEF2C levels were signiﬁcantly higher
(p < 0.05) in CPC-iPSCs than in Fib-iPSCs.
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440ISL1 is a transcription factor expressed with NKX2-5
in cardiac progenitor cells (18), and it is necessary
for the formation of the right ventricle (19). Cardiac
gene expression was assessed during the differenti-
ation process at day 0 pre-induction, day 4, and day
8 after initiation of differentiation (10). Quantitative
polymerase chain reaction demonstrated signiﬁ-
cantly increased expression of the early cardiac
mesodermal marker MESP1 and of cardiovascular
progenitor transcription factors NKX2-5 and ISL1 at
day 4 of induction in CPC-iPSC-CMs, but not in Fib-
iPSC-CMs (Figs. 3A and 3B, Online Figs. 10B and
10C). Cardiogenic transcription factors HAND2,
MYOCD, and GATA4 were also found to be expressed
at signiﬁcantly higher levels in CPC-iPSCs than inFib-iPSCs at day 4 of cardiac differentiation (Fig. 3C,
Online Fig. 10D). By day 8 of induction, only HAND2
andMEF2C presented signiﬁcant differences. At day 8,
HAND2 was higher in Fib-iPSCs, whereas MEF2C was
higher in CPC-iPSCs. These ﬁndings suggest that the
higher efﬁciency of cardiac differentiation observed
for CPC-iPSC-CMs is likely the result of heightened
gene expression of cardiac mesodermal and cardiac
transcription factors early in the differentiation
process.
DNA METHYLATION OF TRANSCRIPTION FACTOR
PROMOTER REGION. Several studies have demon-
strated that the epigenetic memory of somatic donor
cells can result in persistent gene expression, thereby
promoting iPSC differentiation toward somatic cell
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FIGURE 4 Analysis of DNA Methylation Pattern
(A) DNA methylation pattern at the proximal promoter of NKX2-5 after
bisulﬁte pyrosequencing. Salmon circles indicate methylated CpGs, whereas
periwinkle circles indicate unmethylated CpGs. (B) Graph represents the
percentage of methylated CpGs in primary cultures, undifferentiated induced
pluripotent stem cells (iPSCs), and at day 4 of cardiomyocyte (CM)
differentiation from both cardiac progenitor cells (CPCs) and ﬁbroblasts (Fib).
Percentage of methylated CpGs is signiﬁcantly higher in primary ﬁbroblast
cultures and in Fib-iPSCs at day 4 of cardiac differentiation.
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441lineages of origin (20–22). To assess the contribution
of epigenetic memory toward differences in gene
expression observed during the cardiac differentia-
tion process of CPC-iPSCs and Fib-iPSCs, the authors
investigated DNA methylation patterns for the pro-
moter regions of cardiac transcription factors in both
cell types. DNA methylation is 1 of several epige-
netic mechanisms by which gene regulation is regu-
lated. Methylation of CpGs in the promoter region
of a gene typically down-regulates its expression,
whereas efﬁcient promoter demethylation of plurip-
otency genes enhances expression and is necessary
for gene reactivation during reprogramming (20,23).
Bisulﬁte sequencing demonstrated higher methyl-
ation of a region within 2,000 base pairs immediately
upstream of the ﬁrst coding exon of NKX2-5 in pri-
mary ﬁbroblast cultures and Fib-iPSCs, compared
with primary CPC cultures and CPC-iPSCs (Fig. 4A).
Differences in methylation persisted into day 4
of cardiac differentiation (Fig. 4B). The decreased
expression of NKX2.5 found in conjunction with
heightened methylation of the NKX2.5 promoter in
Fib-iPSCs suggests that incomplete resetting of the
preexisting epigenetic state is a strong contributor to
the enriched cardiac gene expression patterns and
differentiation efﬁciencies observed in CPC-iPSCs.
IN VITRO CHARACTERIZATION. Cells generated
from iPSCs such as cardiomyocytes are typically
developmentally immature in comparison with their
adult counterparts (24). Reports have shown that
epigenetic memory can improve maturity and func-
tion of hematopoietic cells generated from blood cell–
derived iPSCs, as compared with iPSCs derived from
other cell types (22). The authors therefore assessed
whether epigenetic memory from CPC-iPSC genera-
tion would result in functional or developmental
differences for Fib-iPSC-CMs derived from the same
donor. Following completion of cardiac differentia-
tion, electrophysiological properties of CPC-iPSC-CMs
and Fib-iPSC-CMs were characterized by calcium
(Ca2þ) imaging, whole-cell patch clamp, and multi-
electrode array (MEA).
Quantiﬁcation of Ca2þ is particularly important
because Ca2þ is 1 of the major players in excitation-
contraction coupling of the heart (25). Furthermore,
iPSC-CMs are characterized by immature Ca2þ
handling properties and incompletely developed
sarcoplasmic reticulum (26). To assess whether
epigenetic memory contributed toward maturity of
CPC-iPSC-CMs, beating EBs were dissociated into
single cells or small clumps of CMs for analysis by the
Ca2þ binding dye Fluo-4 AM. Fluorescence amplitude
resulting from Fluo-4 binding to intracellular Ca2þ
was recorded in both 1 Hz (Online Figs. 11A and 11B)and 2 Hz stimulated beating CMs (Online Figs. 11C
and 11D, Online Videos 1 and 2). Peak ﬂuorescence
amplitude was roughly the same for both somatic
cell sources at 1 Hz and 2 Hz (Fig. 5A, Online Videos 1
and 2), indicating that intracellular Ca2þ levels were
not signiﬁcantly different between the 2 groups.
Other measures of Ca2þ handling such as peak rate of
Ca2þ rise and decline (Figs. 5B and 5C), and time
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FIGURE 5 Characterization of Intracellular Ca2þ Handling
Calcium (Ca2þ) handling properties of single cardiomyocytes after Fluo-4 AM imaging at
day 28  2 post-differentiation. Cytoplasmic Ca2þ levels are directly proportional to
ﬂuorescence intensity. (A) Quantiﬁcation of peak amplitude of Fluo-4 AM dye Ca2þ
transients in cardiac progenitor cell-derived induced pluripotent stem cell-derived car-
diomyocytes (CPC-iPSC-CMs) and ﬁbroblast-derived induced pluripotent stem cell-derived
cardiomyocytes (Fib-iPSC-CMs) when paced at 1 and 2 Hz (Online Videos 1 and 2). (B)
Quantiﬁcation of the peak rate of Ca2þ increase in CPC-iPSC-CMs and Fib-iPSC-CMs at 1-
and 2-Hz pacing. (C) Quantiﬁcation of peak rate of Ca2þ decline presented as ﬂuorescence
ratio (F ratio) per second when iPSC-CMs are paced at 1 and 2 Hz. No statistically sig-
niﬁcant differences were observed between both cell types in any of the studied pa-
rameters (CPC-iPSC-CM: n ¼ 20; Fib-iPSC-CM n ¼ 24). (D) Graph shows the signiﬁcant
differences between 1 and 2 Hz of the Ca2þ peak amplitude in both cell types (CPC-iPSC:
100  16.5% vs 60.6  9.9%, n ¼ 20; Fib-iPSC: 100  12.6% vs 54.7  6.5%, n ¼ 24,
p < 0.05).
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442needed to reach 50% and 90% Ca2þ decline also did
not exhibit any signiﬁcant differences between CPC-
iPSC-CMs and Fib-iPSC-CMs (Online Figs. 11E and 11F).
Both CPC-iPSC-CMs and Fib-iPSC-CMs exhibited
immature Ca2þ-handling properties because increases
in beating rate were found to result in signiﬁcant
decreases in cytosolic Ca2þ transient amplitudes, a
hallmark of developmentally immature cardiac cells
(CPC-iPSC: 100  16.5% vs. 60.6  9.9%, n ¼ 20; Fib-
iPSC: 100  12.6% vs. 54.7  6.5%, n ¼ 24, p < 0.05)
(Fig. 5D) (27).
ELECTROPHYSIOLOGICAL PROPERTIES. Finally,
electrophysiological properties of CPC-iPSC-CMs and
Fib-iPSC-CMs were studied using patch clamp and
MEA. Beating EBs were dissociated into single cells
and seeded on Matrigel-coated coverslips for patch
clamp. Action potential (AP) recordings at day 30  2
identiﬁed nodal-, atrial-, and ventricular-like CMs
among the dissociated cells (Fig. 6A). Measurement of
key AP parameters, such as the frequency of AP, peak
of AP, maximal diastolic potential, AP amplitude, and
AP duration, did not uncover statistically signiﬁcant
differences between CPC-iPSC-CM and Fib-iPSC-CM
subtypes (Fig. 6B). MEA recordings show that spon-
taneous beating and electrical activity were present
in all plated EBs regardless of the somatic cell origin
(Online Figs. 12A and 12B, Online Videos 3 and 4).
Both CPC-iPSC-CM and Fib-iPSC-CM beating EBs
responded to 1 mM of isoproterenol with increased
beating frequency (Online Figs. 12C and 12D). Elec-
trophysiological parameters recorded at day 21  2
demonstrated similar mean beating frequencies
as indicated by the number of beats per minute
(Fig. 6C, Online Videos 3 and 4). Baseline ﬁeld poten-
tial duration (FPD) was slightly higher without
reaching statistical signiﬁcance in CPC-iPSC-EBs
compared with Fib-iPSC-EBs (Fig. 6C). Beating dura-
tion suggested that ventricular-like CMs were the
predominant cell type in both types of EBs, consistent
with single-cell patch clamp data. Taken together, this
study’s in vitro characterization results show no sig-
niﬁcant functional differences between CPC-iPSC-
CMs and Fib-iPSC-CMs.
ENDOTHELIAL AND VASCULAR SMOOTH MUSCLE
DIFFERENTIATION EFFICIENCY. Cardiac progenitor
cells give rise not only to CMs, but also to other cell
types found normally in the heart (7‒9). To investi-
gate whether differences in epigenetic memory could
contribute to differentiation into cell fates other than
CMs, the authors next differentiated both CPC-iPSCs
and Fib-iPSCs into endothelial cell (EC) and vascular
smooth muscle cell (SMC) lineages using deﬁned
protocols (28,29). For EC differentiation, CD31 was
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443used as a selection marker (18). FACS analysis
revealed that the percent of CD31þ cells resulting
from differentiation was signiﬁcantly higher in CPC-
iPSCs when compared with Fib-iPSCs from the same
donor (17.2  4.2% vs. 9.7  1.9%, n ¼ 6; p < 0.05)
(Online Fig. 13A). Immunostaining showed charac-
teristic patterns of CD31 and von Willebrand factor
in both CPC-iPSC-ECs and Fib-iPSC-ECs (Online
Fig. 13B). For smooth muscle differentiation, alpha-
smooth muscle actin (SMA) was used to identify
SMCs. FACS analysis demonstrated that CPC-iPSCs
produced higher numbers of SMCs than Fib-iPSCs
(41.4  8.3% vs. 37.3  8.5%, n ¼ 6; p < 0.05)200 ms
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pluripotent stem cell-derived cardiomyocytes (CPC-iPSC-CMs) and ﬁbro
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patterns of alpha-SMA in both CPC-iPSC-SMCs and
Fib-iPSC-SMCs (Online Fig. 14B).
ASSESSMENT OF FUNCTIONAL RECOVERY AFTER
CELL INJECTION. Because in vitro characterization
revealed no signiﬁcant disparities in CPC-iPSC-CM
and Fib-iPSC-CM function, the authors next com-
pared in vivo therapeutic capacity of both cell types
in a murine model of myocardial infarction (30). To
track survival and engraftment of CPC-iPSC-CMs
and Fib-iPSC-CMs in vivo, the authors ﬁrst trans-
duced CPC-iPSCs and Fib-iPSCs with a lentiviralPC-iPSC-
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444construct driving constitutive expression of ﬁreﬂy
luciferase and green ﬂuorescent protein under the
control of the ubiquitin promoter. CPC-iPSCs and Fib-
iPSCs stably expressing the lentiviral construct were
selected by FACS for isolation and expansion. Fireﬂy
luciferase expression in sorted CPC-iPSCs and Fib-
iPSCs demonstrated no signiﬁcant differences
(Online Figs. 15A and 15B). For delivery into small
animal models, approximately 1 million differenti-
ated iPSC-CMs were further enriched by tetrame-
thylrhodamine methyl ester cell sorting and injected
into the myocardium of SCID beige mice following
ligation of the left anterior descending coronary ar-
tery, as previously described (30). Cell engraftment
was measured noninvasively by bioluminescence
imaging up to 42 days post-surgery (Online Fig. 16).
CPC-iPSC-CMs demonstrated mildly higher levels of
engraftment as comparedwithFib-iPSC-CMs, althoughweek 1 week 2
0
20
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60
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)
*
*
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B
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7 Echocardiographic Evaluation of Cardiac Contractility
resentative images of infarcted hearts pre–myocardial infarction (MI) and at w
tricular fractional shortening (LVFS) for the 3 groups at weeks 1, 2, 4, and 8 po
e 2.both groups exhibited high levels of donor cell death.
Assessment of cardiac functional recovery by echo-
cardiography, however, revealed no signiﬁcant dif-
ferences between the CPC-iPSC-CM and Fib-iPSC-CM
groups at weeks 1, 2, 4, and 8 after MI (Fig. 7A).
Measurements of the left ventricular wall thickness
during systole and diastole did reveal that percentages
of left ventricular fractional shortening (LVFS) were
not signiﬁcantly different between CPC-iPSC-CMs
and Fib-iPSC-CMs over the 8 weeks, but they were
signiﬁcantly higher in both compared with the
phosphate buffered saline control group (n ¼ 8;
p < 0.05) (Fig. 7B). The infarction area itself also was
assessed with post-mortem triphenyltetrazolium
chloride staining (Online Figs. 17A to 17C). Hearts of
animals receiving CPC-iPSC-CMs and Fib-iPSC-CMs
exhibited smaller infarction sizes than did PBS con-
trols. However, no statistically signiﬁcant differencesweek 4 week 8
* *
Week 4 Week 8
eeks 1, 2, 4, and 8 post-infarction. (B) Graph shows mean percent of
st-MI (n ¼ 8). PBS ¼ phosphate buffered saline; other abbreviations as
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445in infarct size were observed between animals
receiving CPC-iPSC-CMs and those receiving Fib-iPSC-
CMs (infarct size for CPC-iPSC-CMs: 21.9  2.4%, n ¼ 5;
Fib-iPSC-CMs: 27.7  3.3%, n ¼ 5; PBS: 42.1  4.2%, n ¼
3; p < 0.05) (Online Fig. 17D).
Taken together, these multiple levels of functional
analysis indicate that animals receiving CPC-iPSC-CMs
and Fib-iPSC-CMs exhibited greater recovery of
cardiac function compared with the PBS controls;
however, no signiﬁcant differences were observed
between the CPC-iPSC-CM and Fib-iPSC-CM cohorts.
DISCUSSION
Because cell fate decisions are largely controlled by
epigenetic processes, understanding the epigenetic
mechanisms underlying stem cell differentiation is
crucial for clinical translation of reprogrammed cells.
Previous reports demonstrated that perturbation of
epigenetic pathways can alter differentiation po-
tential, thereby skewing differentiation toward par-
ticular cell lineages and restricting alternative cell
fates (20,31,32). Thus, characterization of the epige-
netic processes involved in differentiation of plurip-
otent stem cells to cardiac fate would provide valuable
insight into regenerative medicine and drug discovery
platforms (2). In this study, the authors demonstrate
for the ﬁrst time that human iPSCs derived
from cardiac sources exhibit low levels of methylation
on the early mesodermal cardiac promoter NKX2-5.
These CPC-iPSCs are characterized by earlier and
higher expression of cardiac genes that leads to
preferential differentiation of cardiac cell fate.
Furthermore, the study demonstrates that epigenetic
memory of cardiac cell source derivation is elimi-
nated over time (after 40 passages) and does not
result in functional differences in vitro or in vivo.
These results suggest that differences in CpG
methylation in the NKX2-5 promoter may constitute a
crucial mechanism that contributes to different efﬁ-
ciencies observed during cardiac differentiation.
Taken together, these ﬁndings form a broader un-
derstanding of epigenetic regulation of cardiac cell
fate and offer a mechanism to improve cardiac dif-
ferentiation of pluripotent stem cells.
To explain the higher cardiac differentiation efﬁ-
ciency observed in CPC-iPSCs, the authors examined
gene expression levels of representative markers
from each stage of cardiac differentiation. Themarkers
studied included MESP1, HAND2, MYOCD, TBX5,
GATA4, MEF2C, NKX2-5, and ISL1. Expression levels
of cardiovascular progenitor cell markers NKX2-5 and
ISL1 (17) in particular were found to be signiﬁcantly
higher in CPC-iPSCs at day 4, but not signiﬁcantlydifferent from Fib-iPSC expression by day 8 of dif-
ferentiation. The authors believe that the differences
in expression of NKX2-5 and ISL1 contribute to the
disparity in efﬁciency of cardiac, endothelial, and
smooth muscle differentiation in CPC-iPSCs and Fib-
iPSCs, particularly in light of the critical role that
both genes play in the speciﬁcation and development
of cardiomyocytes.
To elucidate the mechanism underlying the differ-
ential expression of transcription factors and cardiac
markers, the study compared methylation patterns
of NKX2-5 in CPC-iPSC-CMs and Fib-iPSC-CMs. The
analysis focused on the methylation patterns of 11
CpGs within the CpG island located within 2,000 bp
upstream of the ﬁrst exon of NKX2-5. Consistent
with the gene expression levels presented for pri-
mary cultures, the authors observed signiﬁcantly
higher CpG methylation in the original ﬁbroblasts
compared with the CPCs. Whereas tissue-speciﬁc
methylation signatures diminished after reprogram-
ming, silencing remained higher in Fib-iPSCs than in
CPC-iPSCs. These ﬁndings suggest that certain
methylation patterns in iPSCs remain close to the
somatic cell types from which they were derived,
thus providing evidence of somatic memory after
reprogramming (20–22). Furthermore, these results
demonstrate that somatic memory in iPSCs is
retained during differentiation (21) and therefore can
be observed during cardiac differentiation.
Despite differences in methylation and cardiac
differentiation efﬁciency, CPC-iPSC-CMs and Fib-
iPSC-CMs were found to exhibit similar sarcomeric
structures and in vitro characteristics when assessed
by patch clamp, Ca2þ handling, and MEA recording.
Ca2þ handling recordings of both CPC-iPSC-CMs
and Fib-iPSC-CMs produced comparable results in
all the analyzed parameters. CPC-iPSC-CMs and
Fib-iPSC-CMs demonstrated equally immature Ca2þ-
handling patterns because higher beating frequencies
were not accompanied by increases in Ca2þ transient
amplitude (27). These results point to an immature
state of iPSC-CMs, consistent with previous reports
(33,34), and they suggest that no residual somatic
memory from CPCs contributes to CM maturation,
which is a current limitation of iPSC-CMs.
To date, no functional comparison of iPSC-CMs
derived from different somatic cell sources from the
same human donor has been performed. Using small
animal echocardiography, the authors found that the
injection of iPSC-CMs improved functional recovery
post-MI as compared with animals receiving saline
alone. However, signiﬁcant differences were not
observed between mice receiving CPC-iPSC-CMs and
those receiving Fib-iPSC-CMs. Taken together, these
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446results prompt the authors to conclude that although
injection of iPSC-CMs improves cardiac function after
MI, the somatic source from which iPSC-CMs are
derived may not be critical.
STUDY LIMITATIONS. First, as reported in other
manuscripts, the therapeutic cells used in this
study’s animal models of MI were observed to un-
dergo high levels of acute donor cell death following
in vivo delivery (35). This ﬁnding suggests that long-
term functional beneﬁts observed in animals
receiving CPC-iPSC-CM and Fib-iPSC-CMs may not be
so much the result of persistent donor iPSC-CM
integration as a response to the release of paracrine
factors in the area of acute ischemic injury (36).
Second, the methylation analysis in this study has
only a correlative association with the differentiation
efﬁciencies that the authors observed. Methylation
assessment demonstrated incomplete silencing of
NKX2-5 in CPC-iPSCs as compared with Fib-iPSCs
that, in turn, was associated with higher levels of
cardiac gene expression in CPC-iPSCs during theCENTRAL ILLUSTRATION Skin Fibroblast and CPC Primary Cultur
Somatic cells were reprogrammed into induced pluripotent stem cells (iP
Sox2, Klf4, and c-Myc. Established iPSCs derived from ﬁbroblasts (Fib-i
cardiomyocytes. Differentiation efﬁciency was found to be higher in cardi
iPSC (Fib-iPSC-CM). In vitro experiments demonstrated that CPC-iPSCs
differentiation compared with Fib-iPSCs. Epigenetic assessment showed
factor NKX2-5 in Fib-iPSC-CMs compared with CPC-iPSC-CMs. However
logical properties were observed. In vivo studies using mouse models of m
CPC-iPSC-CM and Fib-iPSC-CM. In summary, whereas epigenetic memor
functional recovery following cell transplantation is equivalent.cardiac differentiation process, as well as higher
yields of iPSC-CMs. These ﬁndings suggest that
epigenetic memory contributes to differentiation
potential in generation of iPSC-CMs from somatic cell
sources, but it does not rule out other regulatory
mechanisms of gene expression.
CONCLUSIONS
The authors report for the ﬁrst time successful gen-
eration of iPSCs from CPCs and skin ﬁbroblasts of the
same human donors (Central Illustration). Through
close observation of iPSC development under
directed cardiac differentiation protocols, the study
shows that CPC-iPSCs demonstrate a greater efﬁ-
ciency of differentiation into CMs, ECs, and SMCs as
compared with Fib-iPSCs at early passage (<30). This
is most likely the result of incomplete epigenetic
silencing of early cardiac mesodermal transcription
factors such as NKX2-5. Interestingly, the authors did
not observe downstream epigenetic effects on the
sarcomere structure, electrophysiological properties,es Were Established From the Same Human Donors
SCs) by overexpression of the pluripotency transcription factors Oct4,
PSC) and cardiac progenitor cells (CPC-iPSC) were differentiated into
omyocytes derived from CPC-iPSC (CPC-iPSC-CM) compared with Fib-
express higher levels of cardiac transcription factors during cardiac
higher methylation in the promoter region of the cardiac transcription
, no signiﬁcant differences in their morphological and electrophysio-
yocardial infarction showed comparable therapeutic effects between
y improves cardiac differentiation efﬁciency in vitro, the in vivo
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE 1: Human iPSCs
have unlimited self-renewal and pluripotent properties, and their
use also avoids ethical concerns.
COMPETENCY IN MEDICAL KNOWLEDGE 2: Epigenetic
memory in human induced human pluripotent stem cells inﬂu-
ences the efﬁciency of cardiac differentiation through regulation
of gene expression without appreciably affecting the function of
generated cardiomyocytes.
TRANSLATIONAL OUTLOOK: Better understanding of the
effects of somatic cell source selection on cardiac differentiation
could inﬂuence future regenerative medicine and drug discovery
platforms.
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447or restorative function of CPC-iPSC-CMs and Fib-
iPSC-CMs in vitro and in vivo. These ﬁndings identify
an epigenetic regulatory mechanism that is important
for differentiation of iPSCs and that may potentially
inﬂuence future regenerative medicine and drug dis-
covery platforms (2).
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